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The use of MDRD-eGFR to diagnose Chronic Kidney Disease (CKD) is based on the assumption that the 
algorithm will minimize the influence of age, gender and ethnicity that is observed in S-Creatinine concentration 
and thus allow a single cut-off at which further diagnostic and therapeutic actions should be considered. This 
hypothesis is tested in a retrospective analysis of outpatients (N=93,404) and hospitalised (N=35,572) patients in 
UK and Sweden, respectively. An algorithm based on the same model as the MDRD-eGFR algorithm was derived 
from simultaneously measured S-Creatinine concentrations and Iohexol GFR in a subset of 565 patients. The 
combined uncertainty of using this algorithm was estimated to about 15 % which is about three times that of the 
S-Creatinine concentration results. The diagnostic performance of S-Creatinine concentration was evaluated 
using the Iohexol clearance as the reference procedure. It was shown that the diagnostic capacity of MDRD-eGFR, 
as it stands, has no added value compared to S-Creatinine. The gender and age differences of the S-Creatinine 
concentrations in the dataset persist after applying the MDRD-eGFR algorithm. Thus, a general use of the 
MDRD-eGFR does not seem justified. Furthermore the cla i m  t h a t  t h e  e G F R  i s  a d j u s t e d  f o r  b o d y  a r e a  i s  
misleading; the algorithm does not include any body size marker. It is thus a dangerous marker for guiding drug 
administration. 
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Introduction 
Measurement of the S-Creatinine concentration1 
is one of the most frequently requested tests in the 
biochemistry laboratory. Most of the requests may not 
necessarily be related to chronic kidney disease or a 
specific investigation of renal function [1,2]. Never the 
less, health authorities in several countries have ruled 
that each S-Creatinine result shall be accompanied by a 
quantity that is calculated from the S-Creatinine, the 
age and, if applicable, modified for gender (female) 
and ethnicity (Afro-American). This quantity is called 
eGFR2; (estimated glomerular filtration rate). The most 
frequently used algorithm is the 4-parameter MDRD 
algorithm [3,4,5]. It has been reported that this data 
                                                 
1 A note on terminology: The quantity measured is S-Creatinine; 
amount of substance concentration. In the text this is abbreviated to 
S-Creatinine. 
2 Abbreviations: S-Creatinine: S—Creatinine; amount of substance 
concentration (µmol/L). Pt-Iohexol: Patient—Iohexol elimination; 
rate mL/(min x 1.73 m
2). MDRD-eGFR estimated Glomerular 
Filtration Rate using the 4-parameter MDRD equation. eGFR II 
estimated Glomerular Filtration Rate using the presently derived 
equation. LIS: Laboratory Information System. 
 
transformation enhances the diagnosis of chronic 
kidney disease (CKD) as a surrogate marker for 
glomerular filtration rate and is superior to 
S-Creatinine. It is further suggested that the algorithm 
allows a single cut-off value for the diagnosis of CKD, 
particularly stage III [4]. Considering the physiological 
age and gender changes of S-Creatinine the algorithm 
therefore needs to neutralize these effects.  
To validate this hypothesis we present a 
retrospective study in which we apply the 
MDRD-eGFR algorithm to results from primary health 
care in the United Kingdom (UK) and hospitalized 
patients in Sweden (SE). We also derived a 4-term 
algorithm based on the same model as the MDRD 
algorithm using simultaneously measured 
S-Creatinine and Iohexol GFR. The present study thus 
focuses on a comparison of the diagnostic performance 
of eGFR and S-Creatinine, estimating the uncertainty 
of the eGFR and testing the transferability of the eGFR 
between sites. 
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Methods and materials 
Database 
Data from UK included all S-Creatinine results 
from the primary care of the BHR NHS trust (Essex) 
during 2005 (women 49,169, men 44,235). Data from SE 
included all S-Creatinine results from inpatients of the 
Karolinska University Hospital (KS) in Stockholm 
(women 14,124, men 21,648) during a one year period.  
Results from patients above 19 years with 
S-Creatinine between 70 µmol/L and 200 µmol/L were 
partitioned according to gender and age (Table 1 and 
Figure 1). The age was calculated from the year of birth 
to the year of sampling, irrespective of dates of birth or 
sampling. The population in neither of the catchment 
areas allowed singling out a group of African origin 
and no record of ethnicity, was registered in the 
databases.  
Results from all patients in whom S-Creatinine 
and Pt-Glomerular filtration rate (Pt-Iohexol) were 
measured on the same day were obtained from the LIS 
of KS and those fulfilling the inclusion criteria chosen 
(N=565). Results were partitioned according to age 
and gender (Table 1).   
Since all tags that could uniquely identify a 
patient were removed – only age and gender were 
retained – the study did not require permission from 
the Ethics committees. 
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Figure 1. The age-dependent changes of S-Creatinine and MDRD-eGFR for females and males in the Swedish and United Kingdom 
cohorts. Triangles represent females, diamonds males. Int. J. Med. Sci. 2008, 5 
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Table 1 Partitioning of data. Group concentrations and e-GFR values are given as medians and the 25 – 75 percentile interval. 
 Age 
group 
Number Crea 
conc 
Interval Abs 
Diff 
Rel 
conc 
MDRD-eGFRIntervalAbs 
Diff
Rel 
value
Num
ber
Crea 
conc
IntervalAbs 
Diff
Rel 
conc
MDRD-eGFR IntervalAbs 
Diff
Rel 
value
Iohexol 
Number
20-29 485  76 72-82   100  87  79-91   110 3087 78 74-84  100 83  76-89   155 13 
30-39  830  77  72-84  1  101  79 71-85 -8 107 4814 78 74-84 0  93 77 71-82 -6 144 20 
40-49  956  78  73-87  2  103  74 65-79 -5 106 7340 79 75-85 1  94 72 67-78 -5 135 23 
50-59  1763  78  73-88  0  103  70 61-76 -4 106 8972 81 76-87 2  96 68 62-73 -5 127 57 
60-69  2436  80  74-93  2  105  66 56-73 -4 112 9541 83 77-91 2  99 63 57-69 -4 119 43 
70-79 2991  86 76-104 6 113  59  48-68 -7 107 9930 87 79-97 4 104 59  52-65 -5 109 47 
80-89 3698  90 79-111 4 118  55  43-64 -4 100 5495 92 82-106 5 110 54  46-61 -5 100 34 
90- 966 98  83-123  8  129  49  37-59 -6 86                   5 
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49179              322 
                                       
20-29 908  83 76-91   100  103  93-115   107 1902 93 87-100  100 91  83-99   154 20 
30-39 1447  84  77-93  1 101  96  88-106 -7 107 4127 94 88-102 1 101 84  77-91 -7 142 25 
40-49 2075  85  78-94  1 102  90  80-100 -6 105 7444 95 88-103 1 102 79  72-86 -5 134 31 
50-59 3417  86  78-97  1 104  86  74-95 -4 108 9852 96 88-104 1 103 75  68-82 -4 127 62 
60-69 5171  88 79-102 2 106  80  68-91 -6 113 9649 98 90-108 2 105 71  63-78 -4 119 72 
70-79 4541  96 83-118 8 116  71  56-84 -9 113 8093 104 94-116 6 112 65  57-73 -6 109 80 
80-89 3588  104  88-130 8 125  63  48-76 -8 100 3294 110 97-126 6 118 59  50-69 -6 100 27 
90- 501  114  91-143  10  137  56  43-72 -7 89                   5 
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44361              242 
Total    35773              93540              564 
 
Analytical 
Creatinine  
SE. S-Creatinine were measured using Beckman 
LX20 instruments, calibrators and reagents with a 
modified kinetic Jaffe method. The system was 
monitored by routine IQC procedures and 
participation in Equalis EQA system. The laboratory 
reports a measurement uncertainty of 5 % (k=1, i.e. 1 
SD) over the entire reporting interval. The laboratory 
was accredited according to the EN/ISO 15189. 
UK. S-Creatinine were measured using Olympus 
640 analysers. Reagents and calibrators for a modified 
kinetic Jaffe method were obtained from Olympus 
Diagnostics Ltd UK. The quality of results was 
monitored through-out the period by IQC (Randox 
Laboratories Ltd, Ireland) procedures and 
participation in UK NEQAS. The laboratory reports a 
measurement uncertainty of 5 %. The laboratory was 
accredited according to CPA (UK). 
Since there is no prerequisite in the guidelines 
that laboratories shall have harmonized their results 
beyond using a traceable calibrator to abide by the 
recommended cut-off the acceptance by the EQAS was 
regarded as sufficient to disregard any bias. 
Iohexol clearance (Pt-Iohexol) 
Omnipaque®, 5 mL, was injected intravenously 
to fasting, well hydrated patients. Samples were 
drawn before and at 230-240 minutes after the 
injection. The Iohexol concentration was measured by 
HPLC on a C18 column (Zorbax SB-18, Chromtech, 
USA) eluted with Methanol/phosphoric acid and 
assayed using Waters 2487 absorbance detector and 
2795 Separation Module. The system was calibrated 
with Iohexol dissolved in control serum (Autonorm, 
Sero AS, Oslo, Norway). Iopamiro (Astra Zeneca, 
Södertälje, Sweden) was used as internal standard (IS). 
Typically, the IS was eluted twice as fast as Iohexol and 
baseline separation was achieved. Measurement 
uncertainty was 3.2 %. The chromatograms were 
digitized and the Iohexol clearance was estimated 
using a one-point method [5,6]. 
Calculation of MDRD-eGFR and nonlinear fitting  
The eGFR of the UK and SE results were 
calculated using the 4 variable version [4] of the 
MDRD equation. Since UK and SE express 
S-Creatinine in µmol/L the conversion factor 1/88.4 
was incorporated in the original MDRD formula to 
allow direct use of S-Creatinine expressed in µmol/L.  
The S-Creatinine, age and gender were fitted to Int. J. Med. Sci. 2008, 5 
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the measured Pt-Iohexol obtained from the SE results; 
the data set is specified in table 2. The 
Marquardt-Levenberg iterative algorithm that is 
available in SigmaStat was used to model the 
algorithm similar to the MDRD-eGFR algorithm The 
‘constants’ derived for the males were fitted, together 
with a variable factor, to the female Pt-Iohexol values. 
Thus, an algorithm was derived with an ‘if female’ 
factor of 0.82 different from 0.74 stated in the 
MDRD-eGFR algorithm.  
It is reasonable to assume that the fitting is less 
accurate at the extremes of the measuring interval. 
Table 2. Specifications of the cohorts used to derive the eGFR II 
algorithm. Pt-Iohexol in mL/(min x 1.73 m
2) 
 Men  Women 
Number 323  242 
Age median  63  62 
25% percentile  50,8  52 
75% percentile  73  75, 
Pt Iohexol median   63  52 
25% percentile  48  36 
75% percentile  78  71 
Pt Iohexol Max  136  120 
Pt-Iohexol Min  16  15 
ROC analysis 
Using the SE database of Pt-Iohexol as reference, 
the clinical sensitivity, specificity and likelihood ratios 
were calculated for a threshold cut-off of 60 mL/(min x 
1.73 m2) for the MDRD-eGFR and 95 and 115 µmol/L 
for S-Creatinine in women and men, respectively 
(equating to the upper limits of the reference intervals 
recommended by the laboratory at the time of the 
study. It should be pointed out, however, that the 
reference values of the laboratory are just reference 
values estimated as the mean + 2SD of the reference 
population and not meant as action limits).  
Statistics 
The databases and graphs were created with 
Microsoft EXCEL. As appropriate, JMP v 5.1 (SAS 
Institute, Cary NC, USA) and SigmaPlot/Sigmastat v 
10 and 3, respectively (Systat Software, GmbH, 
Erkrath, Germany) were used. Normality was tested 
by the Kolmogorov-Smirnov test. Comparisons 
between results were evaluated using the 
Mann-Whitney rank sum test. 
Results 
Differences between age groups for S-Creatinine 
and MDRD-eGFR results in men and women were 
evaluated by the Kruskal-Wallis “one-way ANOVA by 
rank” followed by the Dunn’s multiple comparison 
procedure. All comparisons of the MDRD results 
showed a significant difference between age groups 
whereas the S-Creatinine in the three lowest age 
groups was not significantly different in the SE cohort 
nor the two lowest in the UK cohort (Figure 1). 
The difference between the creatinine results 
obtained in the UK and SE is small for women but 
about 10 µmol/L for men (Table 1). 
The medians of S-Creatinine were significantly 
different between the genders and this difference was 
retained in the MDRD-eGFR values (p<0.001). The 
ratio of the medians of S-Creatinine and MDRD-eGFR 
between women and men decreased from 0.91 for 
S-Creatinine to 0.79 for MDRD-eGFR in the SE cohort 
and from 0,84 for S-Creatinine to 0.72 for MDRD-eGFR 
in the UK cohort. This indicates that in both cohorts the 
difference between genders is increased by the 
algorithm. It may be pointed out that the ratio between 
the reference values of S-Creatinine for women and 
men used in the laboratory (SE) was 0.82. 
The derived algorithm (table 3 row 4) was 
applied to the creatinine and age data from SE and UK 
to calculate the “eGFR II”. The difference between the 
eGFR II and the MDRD-eGFR was statistically 
significant in all age groups and both cohorts except in 
the highest age groups in both the SE and UK cohorts 
(Table 4). The largest difference between medians of 
the groups were 11 mL/(min x 1.73 m2) and 9 
mL/(min x 1.73 m2), recorded in the youngest 
age-groups of the UK and SE cohorts of females, 
respectively. This indicates that results of the generally 
recommended algorithm and a locally derived 
algorithm will give different results. 
Table 3. Constants and exponents obtained by non-linear fitting of S-Creatinine results to Pt-Iohexol as the dependent variable. Row 
1 summarizes the original MDRD algorithm, rows 2 and 3 those obtained in the SE study, row 4 when the expression in row 2 is 
adjusted to that in row 3 by introducing an ‘if female’ factor and row 5 the algorithm obtained considering both men and women. 
   N  Constant 
(Mass 
units) 
SEM Exp 
crea 
SEM  Exp age  SEM  ’If female’  SEM  R2 Adj 
1  MDRD-eGFR  1628  186  ---  -1,154  --- -0,203 --- 0,742 ---  --- 
2  Women 242  297 53  -0.918  0.068  -0.382  0.045    0.617 
3 Men  323  311  31  -0.852  0.043  -0.344  0.026    0.707 
4  Women 242  311    -0.852   -0.344  0.821  0.012  0.617 
5 All  565  321  33  -0.813  0.040  -0.375  0.026      0.608 
 Int. J. Med. Sci. 2008, 5 
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The medians in the age groups of Pt-Iohexol, 
S-Creatinine and eGFR II are shown in figure 2. This 
material comprised 242 females and 323 males (Table 
1). For clarity the creatinine concentration is expressed 
as 10,000/S-Creatinine. This figure illustrates the 
parallelism between the markers. 
An uncertainty budget [8] was established to 
estimate the combined uncertainty of the eGFR II 
calculations. S-Creatinine of 100 µmol/L equates to an 
MDRD-eGFR of about 60 mL/(min x 1.73 m2). The 
standard uncertainties of the factors and exponents 
obtained in the fitting of the S-Creatinine to the 
Pt-Iohexol (Table 3) were used. The uncertainty of the 
creatinine results was assumed to be 5 %. The major 
sources of the combined uncertainty were S-Creatinine 
(7 %), the factor (321; 42 %), the derived exponent for 
creatinine (-0.813; 1 %), the exponent for the age 
(-0,375; 49 %) and the ‘if female’ factor (1 %). The 
combined uncertainty was about 15 % resulting in an 
interval of the expanded uncertainty (k=2) from 42 
mL/(min x 1.73 m2) to 78 mL/(min x 1.73 m2). The 
statistically significant minimal difference between 
observations (reference difference) at a calculated 
MDRD-eGFR of 60 mL/(min x 1.73 m2) is thus 
() 13 2 15 . 0 60 × ≈ × × × = Δ z z sign  mL/(min x 1.73 
m2). [9] 
At a level of confidence of 95 %, z = 2 and the 
minimal significant difference between two 
observations is thus about 26 mL/(min x 1.73 m2) or 43 
% of the decision value. The corresponding minimal 
difference between S-Creatinine observations is about 
14 µmol/L (14 %) 
() 7 2 2 05 . 0 100 2 × ≈ × × × = Δsign  µmol/L 
ROC curves were calculated (Figure 3) for the 
S-Creatinine and eGFR. At the suggested cut-offs, 
Pt-Iohexol of 60 mL/(min x 1.73 m2) and S-Creatinine 
95 and 115 µmol/L (the upper reference limits of the 
laboratory), respectively, the likelihood ratio (LR) was 
4.4, 3.6, 1.7 and 3.1 for S-Creatinine in men and women 
and MDRD-eGFR, respectively. The z-scores adjusted 
with Yates correction indicate a difference in favor of 
S-Creatinine between the LR of S-Creatinine and 
eGFR. This difference is statistically significant for men 
but not for women (z=2.2 and 1.4, respectively). 
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Figure 2. From top to bottom the inverse S-Creatinine (10000/S-Creatinine, filled triangles), Pt-Iohexol (filled diamonds, solid line) 
and eGFR II (filled squares) of the SE Iohexol data set (women in the right panel). Int. J. Med. Sci. 2008, 5 
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Figure 3. Partial ROC curves. The left panel is based on 342 men, the right on 242 women. Squares refer to S-Creatinine and 
diamonds to eGFR II. Open symbols refer to the predetermined reference limits and cut-offs. 
 
Discussion 
A recent study reported the performance of 
MDRD-eGFR in relation to measured GFR in a large 
diverse population [10]. The present study focuses on 
how the MDRD-eGFR performs in similar cohorts in 
relation to S-Creatinine which is the primary, 
measured quantity. This relation has been poorly 
studied but two independent studies were recently 
published [11,12]. 
Traditionally the kidney function has been 
estimated by the glomerular function through 
“creatinine clearance” although this procedure has 
long been questioned [13]. Major reasons for the 
concern are that creatinine is continuously generated; 
it is secreted and reabsorbed from the tubules and 
excreted by the intestine. In particular the practical 
problems with urine collection are difficult to avoid. 
S-Creatinine varies with age, muscle mass, diet and 
exercise and differs between genders. Other estimates 
of GFR have been based on exogenous substances e.g. 
Inulin and Iohexol. Analytically, the much used Jaffe 
method is liable to interferences by both endogenous, 
e.g. ketone bodies, and exogenous substances e.g. 
certain drugs. The use of a kinetic modification of the 
Jaffe assay has diminished these problems. Enzymatic 
methods, HPLC methods and ID-MS methods are 
available but may be too costly for routine application 
in most laboratories.  
The calibration of S-Creatinine measurements has 
been a major concern [14] and a special factor in the 
MDRD-eGFR algorithm has been derived for 
calibrators that have been assayed by ID-MS [15]. 
Different MDRD-eGFR algorithms are thus in use. This 
will cause an indirect additional increase of the 
interlaboratory uncertainty of the eGFR [16]. The 
trueness of measurements is an often neglected 
problem in formulating common cutoff values, 
set-point values or recommendations. Myers et al. [14] 
concluded that “even if the imprecision is low and the 
assay is standardized to an ID-MS reference measurement 
procedure, if analytical non-specificity bias remains, then 
errors in estimated GFR for individual patients will 
occur”.  
Although the uncertainty contribution by 
S-Creatinine is small this does not mean that changes 
in the calibration of S-Creatinine can be disregarded.  
Accredited laboratories participate in External 
Quality Assessment Schemes (EQAS) or Proficiency 
Testing (PT) that are designed to assess the trueness of 
measurements. The only measurement in eGFR is 
creatinine; therefore EQAS will only evaluate the 
measurement of creatinine, not the calculated quantity.   
The analytical “sensitivity” of S-Creatinine is 
slightly larger than that for MDRD-eGFR, thus if 
S-Creatinine changes from 90 to 115 µmol/L, i.e. 25 
units, then the MDRD-eGFR will decrease from 82 to 
61 mL/(min x 1.73 m2), i.e. 21 units.  
Estimated glomerular filtration rate, eGFR, is 
claimed to eliminate some of the disadvantages of 
S-Creatinine and ‘creatinine clearance’. Many 
algorithms for eGFR include e.g. S-Albumin, S-Urea, 
and patient weight. Thorough evaluations and 
comparisons have been published with extensive 
accounts of kidney function [3,4,5] including a healthy 
cohort [17,18]. The professions have favored the 
4-parameter MDRD [4] algorithm that is based on only 
S-Creatinine, the patient’s age, gender and ethnicity. It 
can be described as the reciprocal of S-Creatinine 
enhanced by multiplying with the reciprocal of the age 
and, if appropriate, adjusted by a factor for the gender 
and ethnicity. An additional factor adjusts the result 
numerically to the order of magnitude of Pt-Iohexol. 
The unit embedded in this factor (mL/(min x 1.73 m2) Int. J. Med. Sci. 2008, 5 
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formally adjusts the dimension of the calculated 
number to that of clearance. The algorithm does not 
include any reference to the size (body area) of the 
actual patient. As a result a 2 m and 100 kg and a 165 m 
50 kg individual of the same age and S-Creatinine 
would have the same MDRD-eGFR expressed in 
mL/(min x 1.73 m2). It is important to understand that 
the regression function may hold true on a population 
basis but not in an individual. The use of eGFR in the 
individual case, after due adjustment for the body size, 
may therefore still be misleading in adjusting the 
d o s a g e  o f  d r u g s .  A n  u n e x p l o r e d  f a c t o r  m a y  b e  t h e  
know anthropometrical differences between 
Americans and others. This is an additional source of 
uncertainty in the use of MDRD-eGFR. 
Only one cut-off value for MDRD-eGFR of 60 
mL/(min x 1.73 m2) (CKD stage III) is recommended 
by the NKDEP [4], for all ages and both sexes, below 
which additional investigations of the kidney function 
should be initiated. Thus the NKDEP assumes that the 
physiological changes of S-Creatinine by age and 
gender will be neutralized by the algorithm. Our 
results unequivocally show that this is not the case 
(Figure 1). The age dependency of MDRD-eGFR was at 
least of the same order of magnitude as that of 
S-Creatinine. Similar results, a decrease of about 7 % 
per decade were recently reported [19]. The K/DOQI 
report [3] suggests a decrease in the GFR with about 1 
mL/min per year of age above 20 years. Our data 
shows that this is not eliminated by the MDRD-eGFR. 
Thus a common cut-off is not applicable to all ages. 
The K/DOQI report further suggests 8 % lower 
GFR [3] values in women than in men but the original 
MDRD-eGFR algorithm suggests a factor of 0.741. Our 
Iohexol study gives a factor of 0.82 ± 0.01 (SEM) which 
is also lower than that expected from the DOQI report 
(0,92). The difference in the ratio between females and 
males of S-Creatinine (0,91) and MDRD (0,79) shows 
that the gender dependence of the markers increases in 
the MDRD-eGFR rather than being reduced or 
eliminated.  
The difference in S-Creatinine between the SE 
and UK cohorts can in part be due to the difference in 
the patient types. Considering the equality between 
the results obtained in SE and UK women it is less 
likely that the difference is due to measurement bias. 
The problem of trueness will necessarily be aggravated by 
introduction of an algorithm in which constants and 
exponents have been derived at a location other than that 
in which it is used. The algorithms estimated in the 
present study were established by fitting data to the 
same model as the original MDRD-eGFR and the 
resulting coefficients and exponents are different 
(Table 3) – but the difference in calculated results are 
not clinically important (Table 4) between adjacent age 
groups in view of the uncertainty attached to the 
MDRD-eGFR results. Also, the large cohorts enhance 
the statistical significance that may not be of the same 
importance in clinical practice. Therefore, the 
algorithms seem reasonably transferable between 
populations at least in the reporting interval and 
excluding the lowest and highest age group.  
Table 4. Medians of eGFR II and difference to the corresponding MDRD-eGFR values (Table 1). Medians and differences are 
expressed in mL/(min x 1.73 m
2). Non-significant differences in bold. 
Age-group Males  Females   Males  Females 
SE  Median Difference Median Difference  UK Median  Difference  Median  Difference 
21-30  95.9  9.2 108.4 4.1   94.2 11.0 98.0  6.9 
31-40  85.1 5.8 95.4 -0.2    83.5 6.4 86.8 3.0 
41-50  76.8 2.8 86.8 -3.1    75.9 3.5 78.9  -0.10 
51-60  71.2 0.8 80.3 -5.4    69.3 1.6 73.0 -1.9 
61-70  66.0 -0.4 74.6 -5.8    64.1 0.7 67.7 -2.9 
71-80 59.3  -0.2  65.8 -4.9    58.7 0.2  61.9 -2.8 
81+ 54.4  -0.3  58.8 -3.7    53.7 0.2  56.5 -2.6 
90+ 48.9  0.3  52.7 -2.6           
 
The course of changes of S-Creatinine, Pt-Iohexol 
and eGFR II over the studied ages is shown in figure 2. 
The changes in Pt-Iohexol and inverted S-Creatinine 
follow each other closely as does the eGFR II. The 
conversion of the S-Creatinine by any of the algorithms 
we tested does thus not contribute to a more effective 
understanding of the kidney function.  
 
The uncertainty of the factors and exponents of 
the original MDRD-eGFR algorithm is not known to 
the authors, however, data from the present study 
(Table 3), provides an estimate of the combined 
uncertainty of 15 % for the results of the eGFR II. This 
may be applicable to the original MDRD-eGFR and Int. J. Med. Sci. 2008, 5 
 
16
indicates an expanded uncertainty of about 20 
mL/(min x 1.73 m2) (k=2) at S-Creatinine 100 µmol/L, 
equating to an eGFR level of about 60 mL/(min x 1.73 
m2). It is interesting to note that the variation that is 
claimed acceptable by the K/DOQI [10] at 
MDRD-eGFR 60 mL/(min x 1.73 m2), is 42-78 mL/(min 
x 1.73 m2) which is compatible with our uncertainty 
calculations (40-80 mL/(min x 1.73 m2)). Since the 
calculated uncertainty corresponds to an 
intralaboratory uncertainty it is an underestimate of 
the interlaboratory uncertainty that should be the basis 
for a recommendation. The uncertainty of S-Creatinine 
is about 14 µmol/L or one third. 
Therefore the use of MDRD-eGFR in diagnosis 
may be misleading and the large uncertainty is a 
disadvantage in monitoring.  
The ROC data (Figure 4) shows that S-Creatinine 
and MDRD-eGFR perform similarly. S-Creatinine 
results, however, are associated with a much smaller 
uncertainty than the MDRD-eGFR and accordingly 
will allow identifying smaller changes in the kidney 
function.  
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Figure 4. Relation between MDRD-eGFR (mL/(min x 1.73 
m
2)) and S-Creatinine (µmol/L). Curves represent (from upper) 
ages 20, 50 and 80 years. Females to the left. Vertical dashed 
lines are suggested creatinine cut-offs. The shaded area 
represents the uncertainty of the MDRD-eGFR based on the 
present study. 
 
Many authors claim that S-Creatinine is a poor 
marker for glomerular filtration rate [20]. It is therefore 
an intriguing thought that a simple algorithm that 
essentially is based on a negative exponent (-1,154) of 
S-Creatinine (equal to 0,87 at S-Creatinine 100 µmol/L) 
and an age compensating factor of about 0,45 (0,54 at 
20 years and 0,42 at 80 years) and a magnifying 
constant factor (174-186) will drastically change the 
diagnostic power of the measurand. On the contrary, 
the algorithm will increase the uncertainty of the result 
and thus the diagnosis. The uncertainty found in our 
derived algorithm transferred to a 95 % level of 
confidence (±18 mL/(min x 1.73 m2)) is almost equal to 
the analytical goal by K/DOQI ±30 % (±18 mL/(min x 
1.73 m2) at 60 mL/(min x 1.73 m2)) [10]. The 
implication of this, as illustrated in figure 4 is that a 
S-Creatinine cut-off of 90 µmol/L and 110 µmol/l for 
females and males, respectively, would correspond to 
a eGFR of 60 mL/(min x 1.73 m2). Measurement of 
S-Creatinine is also easier to standardize than 
algorithms based on regression analysis.  
 
Conclusion 
Transformation of S-Creatinine to eGFR 
according to the MDRD-eGFR algorithm or a similarly 
derived algorithm does not compensate for the 
physiological differences between age groups and 
gender. A common cut-off for additional 
examinations, investigations or diagnosis does thus 
not seem justified, i.e. we either have to fully 
compensate for the effects of gender and age or have 
different cut-offs for the different age groups and 
gender. The present study does not support an 
assumed advantage of factorizing S-Creatinine to 
create a number that superficially resembles that of 
iohexol clearance. Considering the low LR, the pretest 
probability (prevalence of disease) needs to amount to 
about 20 % or higher for either quantity as a single test 
to be of diagnostic value. 
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